相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction
B. E. Phillips et al.
DISEASES OF THE ESOPHAGUS (2013)
HER2 expression and its clinicopathological features in resectable gastric cancer
Yoshiki Kataoka et al.
GASTRIC CANCER (2013)
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections
Hiroaki Nitta et al.
DIAGNOSTIC PATHOLOGY (2012)
Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
Terence C. Chua et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Shinichiro Kiyose et al.
PATHOLOGY INTERNATIONAL (2012)
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Pamela L. Kunz et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
Kab Choong Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization
Laura J. Tafe et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
C. Bozzetti et al.
BRITISH JOURNAL OF CANCER (2011)
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Cristina Gravalos et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Lapatinib Plus Trastuzumab for a Patient with Heavily Pre-treated Gastric Cancer that Progressed after Trastuzumab
Kohei Shitara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Positive Response to Trastuzumab in a Case of HER2-Overexpressing Metastatic Gastric Cancer that Presented as Severe Thrombocytopenia
Jae Hyun Choi et al.
ONKOLOGIE (2011)
Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)
Florian Weissinger et al.
ONKOLOGIE (2011)
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma
Shi-Yan Yan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization
Y. K. Wang et al.
MOLECULAR CYTOGENETICS (2011)
A study of HER2 gene amplification and protein expression in gastric cancer
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
J. D. Barros-Silva et al.
BRITISH JOURNAL OF CANCER (2009)
HER-2 amplification is highly homogenous in gastric cancer
Andreas H. Marx et al.
HUMAN PATHOLOGY (2009)
Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance
Guan Zhen Yu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Xiu Li Zhang et al.
WORLD JOURNAL OF SURGERY (2009)
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
Hiroaki Nitta et al.
DIAGNOSTIC PATHOLOGY (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
Farin Kamangar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Trend in incidence of gastric adenocarcinoma by tumor location from 1969-2004: a study in one referral center in Iran
Afshin Abdi-Rad et al.
DIAGNOSTIC PATHOLOGY (2006)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries
AAM Botterweck et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2000)
分享论文
